Abrogation of Constitutive and Induced Type I and Type III Interferons and Interferon-Stimulated Genes in Keratinocytes by Canine Papillomavirus 2 E6 and E7.
E6
E7
canine
interferon
interferon-stimulated gene
papillomavirus
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
23 06 2020
23 06 2020
Historique:
received:
05
05
2020
revised:
04
06
2020
accepted:
17
06
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Cutaneous papillomaviruses can cause severe, persistent infections and skin cancer in immunodeficient patients, including people with X-linked severe combined immunodeficiency (XSCID). A similar phenotype is observed in a canine model of XSCID; these dogs acquire severe cutaneous papillomavirus infections that can progress to cancer in association with canine papillomavirus type 2 (CPV2). This canine model system provides a natural spontaneous animal model for investigation of papillomavirus infections in immunodeficient patients. Currently, it is unknown if CPV2 can subvert the innate immune system and interfere with its ability to express antiviral cytokines, which are critical in the host defense against viral pathogens. The aim of the current study was to determine if the oncogenes E6 and E7 from CPV2 interfere with expression of antiviral cytokines in keratinocytes, the target cells of papillomavirus infections. We determined that E6 but not E7 interferes with the constitutive expression of some antiviral cytokines, including interferon (IFN)-β and the IFN-stimulated gene IFIT1. Both E6 and E7 interfere with the transcriptional upregulation of the antiviral cytokines in response to stimulation with the dsDNA Poly(dA:dT). In contrast, while E6 also interferes with the transcriptional upregulation of antiviral cytokines in response to stimulation with the dsRNA Poly(I:C), E7 interferes with only a subset of these antiviral cytokines. Finally, we demonstrated that E7 but not E6 abrogates signaling through the type I IFN receptor. Taken together, CPV2 E6 and E7 both impact expression of antiviral cytokines in canine keratinocytes, albeit likely through different mechanisms.
Identifiants
pubmed: 32585804
pii: v12060677
doi: 10.3390/v12060677
pmc: PMC7354437
pii:
doi:
Substances chimiques
Papillomavirus E7 Proteins
0
Interferon-beta
77238-31-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : K01 OD023219
Pays : United States
Références
Virology. 2016 Sep;496:1-8
pubmed: 27236740
PLoS One. 2014 Jul 15;9(7):e102033
pubmed: 25025687
Virus Res. 2017 Mar 2;231:21-33
pubmed: 27890631
Front Oncol. 2019 May 08;9:355
pubmed: 31134154
Clin Microbiol Rev. 2012 Apr;25(2):215-22
pubmed: 22491770
Vet Immunol Immunopathol. 2013 Jun 15;153(3-4):177-86
pubmed: 23557936
J Virol. 2010 May;84(9):4579-86
pubmed: 20181703
PLoS One. 2009;4(3):e4933
pubmed: 19300512
J Immunol. 2008 Aug 15;181(4):2694-704
pubmed: 18684960
Int J Mol Med. 2000 Jun;5(6):661-6
pubmed: 10812019
Immunity. 2015 Jul 21;43(1):15-28
pubmed: 26200010
J Allergy Clin Immunol. 2012 Nov;130(5):1030-48
pubmed: 23036745
J Clin Invest. 2020 Apr 1;130(4):1635-1652
pubmed: 31874109
J Virol. 2006 Jul;80(13):6621-8
pubmed: 16775349
Genes Dev. 1998 Jul 1;12(13):2061-72
pubmed: 9649509
J Biol Chem. 2001 Oct 26;276(43):39765-71
pubmed: 11514542
Nat Commun. 2017 Feb 13;8:14392
pubmed: 28194029
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893940
J Natl Cancer Inst. 2000 May 3;92(9):690-8
pubmed: 10793105
Virology. 2010 May 25;401(1):70-9
pubmed: 20206957
Immunol Res. 1998;17(1-2):63-73
pubmed: 9479568
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
Virology. 2008 Aug 1;377(2):408-18
pubmed: 18519144
Annu Rev Immunol. 2011;29:185-214
pubmed: 21219183
J Virol. 2011 Nov;85(21):11372-80
pubmed: 21849431
J Dermatol Sci. 2014 Sep;75(3):159-66
pubmed: 24928148
Exp Mol Med. 2019 Dec 11;51(12):1-13
pubmed: 31827068
J Virol. 2011 Jan;85(1):178-88
pubmed: 20980500
Curr Probl Dermatol. 2014;45:154-65
pubmed: 24643184
Virology. 2007 Mar 1;359(1):28-36
pubmed: 17034826
Genes Immun. 2011 Sep;12(6):399-414
pubmed: 21490621
J Biol Chem. 2000 Mar 10;275(10):6764-9
pubmed: 10702232
Oncogene. 1999 Oct 14;18(42):5727-37
pubmed: 10523853
PLoS Pathog. 2013;9(5):e1003384
pubmed: 23717208
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Virol. 2020 Jan 31;94(4):
pubmed: 31776268
PLoS Pathog. 2010 Sep 02;6(9):e1001089
pubmed: 20824099
Science. 2015 Oct 30;350(6260):568-71
pubmed: 26405230
Vet Immunol Immunopathol. 1999 Aug 2;69(2-4):127-35
pubmed: 10507300
J Interferon Cytokine Res. 2014 Nov;34(11):848-57
pubmed: 24950142
J Interferon Cytokine Res. 2006 Jul;26(7):455-61
pubmed: 16800784
Cancer Lett. 2002 May 28;179(2):205-12
pubmed: 11888675